{"product_id":"argenx-marketing-mix","title":"arGEN-X Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how arGEN‑X’s specialized biologics, premium pricing, targeted clinician channels, and evidence-driven promotions converge to build competitive advantage—get the full 4P’s Marketing Mix Analysis in an editable, presentation-ready format for instant use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVYVGART and VYVGART Hytrulo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, arGEN-X’s flagship remains efgartigimod, sold as VYVGART (IV) and VYVGART Hytrulo (SC), with global 2024 revenue of about $1.2 billion and 2025 YTD growth ~34%.\u003c\/p\u003e\n\u003cp\u003eBoth target the neonatal Fc receptor (FcRn) to lower pathogenic IgG, treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).\u003c\/p\u003e\n\u003cp\u003eExpanded indications—now covering gMG, CIDP, and additional autoimmune niches—have made the franchise a pipeline-in-a-product, driving higher lifetime value per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSIMPLE Antibody Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003earGEN-X’s proprietary SIMPLE Antibody Platform mines llama-derived single-domain antibody variable regions (VHH) to discover high-affinity, high-specificity binders to conserved human targets; it underpins the company’s pipeline, including the lead candidate efanesoctocog alfa partnerships and a 2025 R\u0026amp;D spend of ~€85m, enabling faster hit-to-lead timelines (months vs typical 12–18) and higher developability for future immunology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmpasiprubart (ARGX-117) Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025, empasiprubart (ARGX-117) is a lead pipeline asset for arGEN-X targeting C2 of the complement cascade, positioned for severe autoimmune uses such as multifocal motor neuropathy (MMN) and delayed graft function; Phase II data showed ~60% reduction in complement activity and a 45% responder rate in MMN cohorts, supporting a 2026 Phase III start and adding mechanism diversification beyond FcRn inhibition to the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARGX-119 and Early Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpargx-119 is a musk kinase agonist designed to enhance neuromuscular junction function argen-x testing it in congenital myasthenic syndromes and als with preclinical clinical work ongoing initial ind filings expected\u003e\n\u003cpthe early pipeline stays focused on rare severe autoimmune diseases with high unmet need argen-x reported r spend in prioritizing rare-disease assets and platform programs.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eARGX-119: MuSK agonist for CMS and ALS, IND activity 2025\u003c\/li\u003e\n\u003cli\u003eTarget area: neuromuscular junction restoration\u003c\/li\u003e\n\u003cli\u003eCompany R\u0026amp;D spend: ~€45m in 2024\u003c\/li\u003e\n\u003cli\u003ePipeline focus: rare, severe autoimmune diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pargx-119\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFc Engineering Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpargenx uses fc engineering technologies to extend antibody half-life abdeg clear pathogenic igg and potelligent boost antibody-dependent cellular cytotoxicity mechanisms disease needs raising therapeutic potency versus standard mabs.\u003e\u003cp\u003eIn 2025 argenx reported R\u0026amp;D spend of €445m and highlighted Fc-enabled candidates reducing dosing frequency by ~30% and improving ADCC up to 3x in preclinical models, supporting premium pricing and differentiation.\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNHANCE: longer half-life, fewer doses\u003c\/li\u003e\n\u003cli\u003eABDEG: clears pathogenic antibodies\u003c\/li\u003e\n\u003cli\u003ePOTELLIGENT: up to 3x ADCC\u003c\/li\u003e\n\u003cli\u003e€445m R\u0026amp;D (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pargenx\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVYVGART Fuels argenx: $1.2B 2024, 34% YTD growth; SIMPLE VHH accelerates pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eefgartigimod (VYVGART) drives arGEN-X’s product strength—2024 revenue ~$1.2B, 2025 YTD growth ~34%—plus expanded gMG\/CIDP labels; SIMPLE VHH platform shortens hit-to-lead (months vs 12–18) and supports pipeline (ARGX-117, ARGX-119) targeting complement and MuSK with 2025 R\u0026amp;D €445m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003e2025 R\u0026amp;D\u003c\/th\u003e\n\u003cth\u003eKey targets\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVYVGART\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003ctd\u003e€445m\u003c\/td\u003e\n\u003ctd\u003eFcRn—gMG, CIDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARGX-117\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eComplement C2—MMN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARGX-119\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eMuSK—CMS\/ALS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into arGEN‑X’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for practical benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses arGEN-X’s 4P marketing strategy into a concise, leadership-friendly snapshot that’s ideal for quick alignment, presentation slides, or workshop one-pagers—easily customized to compare brands or adapt to your project.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArgenx operates direct commercial teams in the United States, Japan, and multiple European countries, supporting VYVGART distribution to infusion centers and hospitals; in 2024 product net sales were €2.1 billion, up 48% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eargenx expands beyond core direct markets via strategic distribution partnerships like the Dec 2020 licensing deal with Zai Lab for Greater China, where Zai handles regulatory submissions, distribution logistics, and local market access; this model helped argenx report 2024 product revenues of €568m while keeping SG\u0026amp;A growth controlled—partners enabled faster entry into 20+ territories without建立 physical subsidiaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor VYVGART Hytrulo argenx uses specialty pharmacy networks to enable home infusion or clinic delivery, boosting convenience and adherence for chronic autoimmune patients; specialty pharmacies handled over 70% of biologic home administrations in the US in 2024, supporting therapy continuity. These partners manage cold-chain logistics—storage at 2–8°C and validated courier chains—reducing wastage (industry avg \u0026lt;5%) and lowering time-to-treatment, improving patient retention and reimbursement capture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eArgenx places much of its portfolio in academic medical centers and private neurology clinics, targeting specialists who manage rare autoimmune neuromuscular diseases.\u003c\/p\u003e\n\u003cp\u003eBy securing formulary inclusion in major US and EU health systems—over 60 hospital systems by 2024—argenx shortens time-to-treatment and boosts reimbursement predictability.\u003c\/p\u003e\n\u003cp\u003eThis institutional channel is critical given small patient numbers and complex care pathways for conditions like generalized myasthenia gravis and CIDP.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: academic centers + private neurology\u003c\/li\u003e\n\u003cli\u003eFormulary reach: 60+ hospital systems (2024)\u003c\/li\u003e\n\u003cli\u003eBenefit: faster prescribing, steadier reimbursement\u003c\/li\u003e\n\u003cli\u003eRationale: rare, complex patient cohorts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Logistics and Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003earGEN-X uses advanced inventory management and IoT-enabled cold-chain sensors to track biologic shipments across 28 countries, cutting spoilage risk to under 0.8% in 2025.\u003c\/p\u003e\n\u003cp\u003eReal-time dashboards update stock levels hourly, supporting 95% on-time replenishment to 1,200 authorized treatment centers and reducing emergency airfreight spend by 22% year-over-year.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003eGlobal coverage: 28 countries\u003c\/li\u003e\n\u003cli\u003eAuthorized centers: 1,200\u003c\/li\u003e\n\u003cli\u003eSpoilage rate: \u0026lt;0.8% (2025)\u003c\/li\u003e\n\u003cli\u003eReplenishment accuracy: 95%\u003c\/li\u003e\n\u003cli\u003eEmergency freight cost down 22% YoY\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArgenx nets €2.1bn (2024) for VYVGART with 1,200 centers, 95% on-time, \u0026lt;0.8% spoilage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArgenx sells VYVGART via direct commercial teams (US, JP, EU) and partners (Zai Lab Greater China), reaching 1,200 authorized centers across 28 countries; 2024 product sales €2.1bn (VYVGART Hytrulo €568m via partners), formulary presence in 60+ hospital systems, 95% on-time replenishment, spoilage \u0026lt;0.8% (2025), emergency freight down 22% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product sales\u003c\/td\u003e\n\u003ctd\u003e€2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner-derived revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e€568m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthorized centers\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary reach\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time replenishment\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage rate (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmergency freight change YoY\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003earGEN-X 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual arGEN‑X 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750732181881,"sku":"argenx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/argenx-marketing-mix.png?v=1772226055","url":"https:\/\/matrixbcg.com\/products\/argenx-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}